MRK Stock Merck & Co., Inc.
BUY US · NYSELarge-scale cash generation and pipeline diversification provide defensive value despite patent risks.
Future value: $159.76 (+13.62%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Valuation support and pipeline catalysts attract institutional interest.
- ▾Below 50-day MA (-4.18%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (78.2% of range) — strength
Is MRK a buy right now?
Trend: MRK is trading below the 50-day average (-0.93%), RSI 56 — neutral momentum, with a 3-month return of +11.10%.
Valuation & quality: Merck & Co., Inc. trades on a trailing P/E of 111.6, forward P/E 15.2, PEG 2.72, price-to-book 8.28; fundamentals show net margin 4.8%, return on equity 7.0%, revenue growth 5.1% year on year.
Analyst consensus: 25 analysts have a mean 12-month price target of $159.76 (+13.6% vs the last close; range $105.00 – $186.00), consensus rating “buy”.
Income: trailing dividend yield 2.34%.
Our screen: BUY (score 3) — Large-scale cash generation and pipeline diversification provide defensive value despite patent risks.
Computed from end-of-day data; not personal advice.
Our track record with MRK
Our simulated $10,000 funds have traded MRK 1 time — 0 of 1 closed trade profitable.
| Fund | Bought | Sold | Return |
|---|---|---|---|
| US Low-risk | 2026-10-12 @ $145.60 | 2026-10-14 @ $141.98 · AI review sell | -2.49% |
Paper trades from our simulated funds at real end-of-day prices; past results don't predict future returns.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -2.90% | -9.20% | +8.70% | +8.20% | +1.30% | +13.50% | -1.70% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo…
Sector: Healthcare · Industry: Drug Manufacturers - General · United States · 73,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.